do you have patients on daratumumab who need to be tested ...multiple myeloma, daratumumab-specific,...

Why test your patients? Multiple Myeloma, Daratumumab-Specific, Immunofixation test helps multiple myeloma patients treated with daratumumab to tease out monoclonal antibody interference and monitor their response to treatment. DARZALEX® (daratumumab; Janssen Biotech) is a CD38-directed cytolytic antibody indicated 1) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and 2) as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent. In patients being treated with Daratumumab, it is difficult to differentiate between the endogenous myeloma protein (M protein) and the daratumumab protein with immunofixation electrophoresis assay. Quest Diagnostics has launched the FDA modified: Multiple Myeloma, Daratumumab-Specific, Immunofixation. This is a serum test detected by a gel shift assay to distinguish daratumumab from endogenous M-protein by IFE to enable assessment of the M protein. For multiple myeloma patients being treated with Daratumumab this test can avoid unnecessary follow-up testing and allow more accurate interpretation of depth of response to treatment. The test is available at Quest’s Nichols Institute, San Juan Capistrano, CA. Quest Diagnostics now offers the Multiple Myeloma, Daratumumab-Specific, Immunofixation test for your multiple myeloma patients on Daratumumab Do you have patients on Daratumumab who need to be tested for clinical response? QuestDiagnostics.com Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks - ® and ™ - are the property of their respective owners. © 2017 Quest Diagnostics Incorporated. All rights reserved. SB6762 3/2017 Multiple Myeloma, Daratumumab-Specific, Immunofixation NTC 94514 CPT 86334 Sample Type: Blood/serum

Upload: others

Post on 05-Jun-2020

5 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: Do you have patients on Daratumumab who need to be tested ...Multiple Myeloma, Daratumumab-Specific, Immunofixation test helps multiple myeloma patients treated with daratumumab to

Why test your patients?

Multiple Myeloma, Daratumumab-Specific, Immunofixation test helps multiple myeloma patients treated with daratumumab to tease out monoclonal antibody interference and monitor their response to treatment.

DARZALEX® (daratumumab; Janssen Biotech) is a CD38-directed cytolytic antibody indicated 1) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and 2) as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.

In patients being treated with Daratumumab, it is difficult to differentiate between the endogenous myeloma protein (M protein) and the daratumumab protein with immunofixation electrophoresis assay.

Quest Diagnostics has launched the FDA modified: Multiple Myeloma, Daratumumab-Specific, Immunofixation. This is a serum test detected by a gel shift assay to distinguish daratumumab from endogenous M-protein by IFE to enable assessment of the M protein.

For multiple myeloma patients being treated with Daratumumab this test can avoid unnecessary follow-up testing and allow more accurate interpretation of depth of response to treatment.

The test is available at Quest’s Nichols Institute, San Juan Capistrano, CA.

Quest Diagnostics now offers the Multiple Myeloma, Daratumumab-Specific, Immunofixation test for your multiple myeloma patients on Daratumumab

Do you have patients on Daratumumab who need to be tested for clinical response?

QuestDiagnostics.comQuest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks - ® and ™ - are the property of their respective owners. © 2017 Quest Diagnostics Incorporated. All rights reserved. SB6762 3/2017

Multiple Myeloma, Daratumumab-Specific, Immunofixation

NTC94514

CPT 86334

Sample Type: Blood/serum

Daratumumab and anti-CD38 therapy: a new front in myeloma ... Program Handouts...Most patients developed weakly positive indirect antiglobulin test. Reactive with all cells tested

Myeloma Primary Care - hgs.uhb.nhs.uk€¦ · Myeloma patients in asymptomatic patients without CRABI = asymptomatic or smouldering myeloma until this revision in 2014. Patients with

Multiple Myeloma beyond Daratumumab

Prevention and Management of Cardiotoxicity in Patients With Multiple Myeloma

Abnormal Function B Lymphocytes from Peripheral of ... · of Multiple Myeloma Patients ... 44 multiple myeloma patients and 18 individuals with monoclonal ... Plasma IgM levels were

Optimizing Care for Patients with Relapsed/Refractory Multiple Myeloma

Infopack for relapsed and/or refractory myeloma patients

Myeloma - CancerQuest › ... › myeloma.pdf · often present in abnormally large numbers in patients with myeloma (see Figure 4). The myeloma cells accumulate in an uncontrolled